Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.
Tumors|Oncology|Solid Tumors
DRUG: panitumumab (ABX-EGF)|DRUG: Panitumumab
To evaluate the safety and PK of 2 dose schedules of panitumumab in subjects with advanced solid tumors, refractory to or with no available standard therapy., 2 years
To asses the immunogenicity and efficacy of 2 dose schedules of panitumumab in subjects with advanced solid tumors., 2 years
The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.